The independent medical news service

Previously treated patients with HER2-positive metastatic breast cancer derive a significant progression-free survival benefit from trastuzumab deruxtecan relative to trastuzumab emtansine, find the DESTINY-Breast03 investigators.

Adding carboplatin to neoadjuvant paclitaxel is sufficient to boost the outcomes of patients with triple-negative breast cancer, with no further improvement from the addition of veliparib to the dual regimen, confirms a follow-up analysis of the BrighTNess trial.

Residual cancer burden offers prognostic information after neoadjuvant chemotherapy across breast cancer subtypes and treatments, show data from I-SPY2.

Young women who undergo mastectomy for breast cancer report poorer quality of life than those treated with breast conserving therapy more than 5 years after surgery, particularly when they also receive radiotherapy, research shows.

The number of new cancer diagnoses during the first year of the COVID-19 pandemic was lower than in the prepandemic period, report US researchers.

Cardioprotective pharmacologic therapy may be effective against anthracycline-related subclinical heart damage in women with nonmetastatic breast cancer, with bisoprolol potentially offering greater benefits than ramipril, interim SAFE study data suggest.

Around a fifth of people with cancer included in the French COVIPACT study reported symptoms consistent with post-traumatic stress disorder during the first national lockdown in response to the COVID-19 outbreak, find the investigators.

HER2-negative breast tumors with low hormone receptor positivity could be treated similarly to triple-negative tumors, suggests research from Germany that showed similar survival outcomes between the two groups.

A US study has found that breast cancer screening rates declined during the COVID-19 pandemic, with the largest reductions among Black and Latinx women, which may exacerbate pre-existing disparities.

The final analysis of the SOLE trial has shown no significant difference in the outcomes of postmenopausal women with hormone receptor-positive breast cancer who received extended intermittent or continuous adjuvant letrozole.

Study findings suggest that using a genomic-adjusted radiation dose may help overcome the heterogeneity of tumor response to radiotherapy and improve overall survival for patients with cancer.

Genetic testing should be expanded to include older women with breast cancer, especially those with triple-negative or estrogen receptor-negative disease, suggest US researchers.

The seropositivity rate in response to the Pfizer–BioNTech (BNT162b2) vaccine against SARS-CoV-2 remains high around 4 months after the second dose in cancer patients undergoing active therapy, report Israeli researchers.

Statin use in the 12 months after diagnosis of early-stage triple-negative breast cancer is associated with improved survival in older women, findings indicate.

A major histocompatibility complex-II tumor cell expression rate of 5% or more could identify HER2-negative breast cancer patients likely to benefit from the addition of PD-1 or PD-L1 inhibitors to standard neoadjuvant chemotherapy, research findings suggest.

Patients with breast cancer may be at increased risk for early discontinuation of adjuvant endocrine therapy if they have depression, or poor physical or social wellbeing before treatment initiation, suggests a post-hoc analysis of the TAILORx trial.

Read more on this decision here

The phase 3 SALSA trial has demonstrated no benefit of extending aromatase inhibitor therapy by 5 years versus 2 years in postmenopausal women with hormone receptor-positive breast cancer who have already received 5 years of adjuvant endocrine therapy.

A single-center study of women undergoing breast imaging after COVID-19 vaccination has revealed a higher than usual rate of axillary adenopathy.

Remote symptom monitoring  is associated with a reduced symptom burden and improved quality of life in people with cancer receiving adjuvant chemotherapy, trial findings indicate.